ATE438096T1 - Hla-e bindung zu cd94/nkg2+ zellen - Google Patents

Hla-e bindung zu cd94/nkg2+ zellen

Info

Publication number
ATE438096T1
ATE438096T1 AT98959027T AT98959027T ATE438096T1 AT E438096 T1 ATE438096 T1 AT E438096T1 AT 98959027 T AT98959027 T AT 98959027T AT 98959027 T AT98959027 T AT 98959027T AT E438096 T1 ATE438096 T1 AT E438096T1
Authority
AT
Austria
Prior art keywords
cells
nkg2
hla
binding
inactivation
Prior art date
Application number
AT98959027T
Other languages
German (de)
English (en)
Inventor
Veronique Braud
David Allan
Graham Ogg
Christopher O'callaghan
Andrew Mcmichael
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE438096T1 publication Critical patent/ATE438096T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pregnancy & Childbirth (AREA)
AT98959027T 1997-12-04 1998-12-04 Hla-e bindung zu cd94/nkg2+ zellen ATE438096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9725764.6A GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding
PCT/GB1998/003686 WO1999028748A2 (en) 1997-12-04 1998-12-04 Hla-e binding

Publications (1)

Publication Number Publication Date
ATE438096T1 true ATE438096T1 (de) 2009-08-15

Family

ID=10823165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98959027T ATE438096T1 (de) 1997-12-04 1998-12-04 Hla-e bindung zu cd94/nkg2+ zellen

Country Status (7)

Country Link
US (3) US7410767B1 (cg-RX-API-DMAC10.html)
EP (2) EP1036327B1 (cg-RX-API-DMAC10.html)
JP (4) JP4336451B2 (cg-RX-API-DMAC10.html)
AT (1) ATE438096T1 (cg-RX-API-DMAC10.html)
DE (1) DE69841020D1 (cg-RX-API-DMAC10.html)
GB (1) GB9725764D0 (cg-RX-API-DMAC10.html)
WO (1) WO1999028748A2 (cg-RX-API-DMAC10.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
EP1423140A2 (en) * 2001-07-31 2004-06-02 Karl Petter Söderström Compositions and methods for modulation of immune responses
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
CA2541241A1 (en) * 2003-08-26 2005-03-03 Danmarks Tekniske Universitet A continuous process for the assembly of macromolecular substances and the subsequent capture and isolation of a macromolecular assembly, and a system suitable for the process
EP1766393A4 (en) * 2004-05-07 2008-06-18 Beckman Coulter Inc MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS
EP2226332A1 (en) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
US7932055B2 (en) * 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
US11471486B2 (en) 2012-09-04 2022-10-18 Inven2 As Selective and controlled expansion of educated NK cells
US20150037304A1 (en) * 2013-03-12 2015-02-05 Sangamo Biosciences, Inc. Methods and compositions for modification of hla
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
WO2015142661A1 (en) * 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
WO2015148960A1 (en) * 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
KR20250007689A (ko) 2014-09-16 2025-01-14 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
SMT202100280T1 (it) 2016-01-21 2021-07-12 Innate Pharma Neutralizzazione delle vie inibitorie nei linfociti
EP3573997A4 (en) * 2017-01-24 2020-12-09 Abexxa Biologics, Inc. METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
CN112351795A (zh) * 2018-02-23 2021-02-09 安贝科思生物制剂公司 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
US11464840B2 (en) 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers
TWI924623B (zh) 2018-03-13 2026-05-11 法商天賜製藥公司 頭頸癌之治療
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
JP2022510207A (ja) * 2018-12-02 2022-01-26 フェイト セラピューティクス，インコーポレイテッド 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
EP4221752A4 (en) 2020-09-30 2024-12-04 Dren Bio, Inc. ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
CA3229447A1 (en) * 2021-08-20 2023-02-23 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
EP4569117A2 (en) * 2022-08-11 2025-06-18 The Trustees of The University of Pennsylvania Universal t cells and compositions and methods of use thereof
EP4688859A1 (en) * 2023-03-24 2026-02-11 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
WO2026016730A1 (zh) * 2024-07-17 2026-01-22 广州瑞风生物科技股份有限公司 一种突变hla-e重链、hla-e三聚体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112487A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112486A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112485A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding

Also Published As

Publication number Publication date
US7410767B1 (en) 2008-08-12
WO1999028748A3 (en) 1999-12-23
EP2144065A1 (en) 2010-01-13
US20150361180A1 (en) 2015-12-17
JP5268828B2 (ja) 2013-08-21
JP4336451B2 (ja) 2009-09-30
JP2002513541A (ja) 2002-05-14
DE69841020D1 (de) 2009-09-10
JP2009106299A (ja) 2009-05-21
US20080274475A1 (en) 2008-11-06
EP1036327A2 (en) 2000-09-20
JP2013081478A (ja) 2013-05-09
WO1999028748A2 (en) 1999-06-10
EP1036327B1 (en) 2009-07-29
JP2010024233A (ja) 2010-02-04
GB9725764D0 (en) 1998-02-04
JP4437160B2 (ja) 2010-03-24

Similar Documents

Publication Publication Date Title
DE69841020D1 (de) HLA-E Bindung zu CD94/NKG2+ Zellen
AR003466A1 (es) Compuestos 14-hidroxi-2-desoxoparahercuamida b
DE3786407D1 (de) Nukleierungssystem fuer polyamide.
DE69728758D1 (de) Vorrichtung zur kopplung von übertragungselementen
EP1104303A4 (en) CARBOHYDRATES OR 2'-MODIFIED OLIGONUCLEOTIDS WITH ALTERNATING INTERNAL CLEOSIDE BINDINGS
DE69801898D1 (de) Vorrichtung zur isolierung von lastschwingungen
NZ312327A (en) Controlling hemipteran insect pests with bacillus thuringiensis
ATE194325T1 (de) Insektizide düngemischungen
BR9804676A (pt) Processo para o teste de um dispositivo de embreagem automatizado.
AR015687A2 (es) Gen aislado que codifica acil transferasa
DK1082373T3 (da) Klæbemiddelsystem
EA199800867A1 (ru) Соединения тетрагидробетакарболина
EA199900950A1 (ru) Маркер для отбора
ES2186807T3 (es) Inhibidores de trombina.
DE69725459D1 (de) Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
BG100248A (bg) Инхибитори на скваленсинтетаза
ES2123641T3 (es) Secuencias de acidos nucleicos que codifican o que son complementarias a secuencias de acidos nucleicos que codifican para el receptor de la interleucina 9.
BR9712532A (pt) Método para aumentar o nìvel de expressão de um transgene população de células monocotiledÈneas,plantas e sementes
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
PE20399A1 (es) Muteina ob
DE69934188D1 (de) Vorrichtung zur Dämpfung von Drehmomentschwankungen
ATE239369T1 (de) Vorrichtung zum vertreiben von schädlingen
MX9804043A (es) Composiciones parasiticidas a base de polisiloxanos ciclicos.
DE59709012D1 (de) Verwendung von primern für universelle fingerprint-analysen
ATE307201T1 (de) Srcr domäne-enthaltendes protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties